Targeting Leptomeningeal Brain Tumors With CAR T Therapy
Manuel Litchman, MD, the president, chief executive officer, and director of Mustang Bio, discussed upcoming research on MB-101 cell therapy.
Advantages of Manufacturing Cell Therapies In-House
The chief technology and chief executive officer of Mustang Bio discussed the company’s integrated approach to drug development.
CD20-Targeted Gene Therapy
Manuel Litchman, MD, the president, chief executive officer, and director of Mustang Bio discussed the company’s lead and second program.
Investigating CAR T in Lymphoma, Leukemia, and Solid Tumors
The president, chief executive officer, and director of Mustang Bio discussed the company’s pipeline.
Benefits of Using CART-T Therapies to Treat Rare Cancers
Manuel Litchman, MD, President and CEO of Mustang Bio Inc, highlights the advantages of using CAR-T therapies as treatments for rare cancers.